Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer.

Authors: Zhao, Zhiguo, Patel, Pratik A., Slatnick, Leonora, Sitthi-Amorn, Anna, Bielamowicz, Kevin J., Nunez, Farranaz A., Walsh, Alexandria M., Hess, Jennifer, Rossoff, Jenna, Elgarten, Caitlin, Myers, Regina, Saab, Raya, Basbous, Maya, Mccormick, Meghan, Aftandilian, Catherine, Richards, Rebecca, Nessle, C. Nathan, Tribble, Alison C., Sheth Bhutada, Jessica K., Coven, Scott L.

Source: Journal of Clinical Oncology; 3/1/2024, Vol. 42 Issue 7, p832-841, 11p

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

Authors: Sonneveld, Pieter, Moreau, Philippe, Dimopoulos, Meletios A., Quach, Hang, Joy Ho, P., Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Driessen, Christoph, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Bladé, Joan, Boccadoro, Mario, Rodriguez-Otero, Paula

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S236-S236

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

Authors: Dimopoulos, Meletios A., Sonneveld, Pieter, Rodriguez-Otero, Paula, Quach, Hang, Joy Ho, P., Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Driessen, Christoph, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Bladé, Joan, Boccadoro, Mario, Moreau, Philippe

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S235-S235

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Authors: Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J, Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodríguez Otero, Paula, Bladé, Joan, Moreau, Philippe

Source: In Blood 21 November 2023 142 Supplement 2

This result is not displayed to guests.
Login for full access.